Dr Reddy’s Laboratories will next month launch its generics portfolio in France as it continues to expand its European commercial operations.
The firm will introduce oncology and anti-infective generic products in the French hospital market, following their recent launch in the Spanish and Italian hospital markets.
Dr Reddy’s is also looking to further strengthen its presence in Southern Europe – where its current portfolio spans gastrointestinal, cardiovascular, pain management, anti-fungal and dermatology products – with the introduction of HIV treatments in Italy and Spain later this year.
Adbijit Mukherjee, chief operating officer of Dr Reddy’s, said: “It is our constant endeavour to enhance the reach of our affordable and difficult-to-produce drugs.
“Our business expansion in Europe is testimony to Dr Reddy’s commitment to ensure access to affordable medicine for patients across the globe.”
The Indian pharma company’s European operations are now based in Basel, after they moved to Switzerland from the UK around six years ago.
Meanwhile, in its home country it is targeting a number of therapy areas, having agreed a €118m deal with UCB in 2015 to acquire a portfolio of dermatology, respiratory and pediatric treatments. The market for this area is expected to grow by almost $40bn to reach $54bn by 2020.